132 related articles for article (PubMed ID: 27699813)
21. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
22. Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy.
Celestini V; Tezil T; Russo L; Fasano C; Sanese P; Forte G; Peserico A; Lepore Signorile M; Longo G; De Rasmo D; Signorile A; Gadaleta RM; Scialpi N; Terao M; Garattini E; Cocco T; Villani G; Moschetta A; Grossi V; Simone C
Cell Death Dis; 2018 Feb; 9(2):231. PubMed ID: 29445193
[TBL] [Abstract][Full Text] [Related]
23. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth.
Shiota M; Izumi H; Tanimoto A; Takahashi M; Miyamoto N; Kashiwagi E; Kidani A; Hirano G; Masubuchi D; Fukunaka Y; Yasuniwa Y; Naito S; Nishizawa S; Sasaguri Y; Kohno K
Cancer Res; 2009 Apr; 69(7):3148-56. PubMed ID: 19318582
[TBL] [Abstract][Full Text] [Related]
24. S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer.
Zhu W; Xue Y; Liang C; Zhang R; Zhang Z; Li H; Su D; Liang X; Zhang Y; Huang Q; Liu M; Li L; Li D; Zhao AZ; Liu Y
Tumour Biol; 2016 Sep; 37(9):12241-12250. PubMed ID: 27240591
[TBL] [Abstract][Full Text] [Related]
25. FOXO3a and Its Regulators in Prostate Cancer.
Habrowska-Górczyńska DE; Kozieł MJ; Kowalska K; Piastowska-Ciesielska AW
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830408
[TBL] [Abstract][Full Text] [Related]
26. FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death.
Brucker DP; Maurer GD; Harter PN; Rieger J; Steinbach JP
Int J Oncol; 2016 Dec; 49(6):2399-2410. PubMed ID: 27840901
[TBL] [Abstract][Full Text] [Related]
27. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
Law JH; Li Y; To K; Wang M; Astanehe A; Lambie K; Dhillon J; Jones SJ; Gleave ME; Eaves CJ; Dunn SE
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844753
[TBL] [Abstract][Full Text] [Related]
28. Transcription Factor FOXO3a Overexpression Inhibits the Progression of Neuroblastoma by Regulating the miR-21/SPRY2/ERK Axis.
Chen J; Xu Y; Wu P; Chen X; Weng W; Li D
World Neurosurg; 2022 Aug; 164():e99-e112. PubMed ID: 35405317
[TBL] [Abstract][Full Text] [Related]
29. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
30. β-arrestin1-medieated inhibition of FOXO3a contributes to prostate cancer cell growth in vitro and in vivo.
Kong Z; Deng T; Zhang M; Zhao Z; Liu Y; Luo L; Cai C; Wu W; Duan X
Cancer Sci; 2018 Jun; 109(6):1834-1842. PubMed ID: 29676828
[TBL] [Abstract][Full Text] [Related]
31. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
[TBL] [Abstract][Full Text] [Related]
32. YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence.
Sheridan CM; Grogan TR; Nguyen HG; Galet C; Rettig MB; Hsieh AC; Ruggero D
Oncotarget; 2015 Apr; 6(10):7470-80. PubMed ID: 25797255
[TBL] [Abstract][Full Text] [Related]
33. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
34. miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A.
Qiu X; Dou Y
Biomed Pharmacother; 2017 Apr; 88():430-435. PubMed ID: 28122308
[TBL] [Abstract][Full Text] [Related]
35. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity.
Sunayama J; Sato A; Matsuda K; Tachibana K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2011 Sep; 29(9):1327-37. PubMed ID: 21793107
[TBL] [Abstract][Full Text] [Related]
36. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
Cornforth AN; Davis JS; Khanifar E; Nastiuk KL; Krolewski JJ
Oncogene; 2008 Jul; 27(32):4422-33. PubMed ID: 18391984
[TBL] [Abstract][Full Text] [Related]
37. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
38. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor.
Chandramohan V; Mineva ND; Burke B; Jeay S; Wu M; Shen J; Yang W; Hann SR; Sonenshein GE
J Cell Biochem; 2008 Aug; 104(6):2091-106. PubMed ID: 18393360
[TBL] [Abstract][Full Text] [Related]
39. PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer.
Liu W; Sui F; Liu J; Wang M; Tian S; Ji M; Shi B; Hou P
Oncotarget; 2016 Aug; 7(34):54744-54757. PubMed ID: 27458157
[TBL] [Abstract][Full Text] [Related]
40. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.
Zhang L; Yang X; Li X; Li C; Zhao L; Zhou Y; Hou H
Int J Mol Med; 2015 Oct; 36(4):957-66. PubMed ID: 26310353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
